CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3)

Muscle Spasticity Clinical Trial

Official title:

A Randomized, Double-blind, Active Drug Controlled, Multi-Center, Phase I/III Clinical Trial to Evaluate the Efficacy and Safety of CORETOX® in Treatment of Post Stroke Upper Limb Spasticity

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03289702
• Other study ID #: MT03-KR16MST907 (Phase3)
• Status: Completed
• Phase: Phase 3
• Start date: November 13, 2017
• Est. completion date: November 9, 2018

Study information

• Verified date: December 2021
• Source: Medy-Tox
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of CORETOX® in the treatment of post-stroke upper limb spasticity

Recruitment information / eligibility

• Status: Completed
• Enrollment: 220
• Est. completion date: November 9, 2018
• Est. primary completion date: June 30, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

• Male or female patients = 19 years

• = 6 months since the last stroke

• = 2 points in the focal spasticity of wrist flexor and = 1 point at least one of elbow flexor and finger flexor as measured on MAS(0 to 4)

• Informed consent has been obtained

Exclusion Criteria:

• Neuromuscular disorders such as Lambert-Eaton syndrome, myasthenia gravis, or amyotrophic lateral sclerosis

• History(within 4 months of screening visit) or planned(during study period) treatment with phenol or alcohol injection or surgery in the target limb

• History(within 4 months of screening visit) or planned(during study period) treatment with tendon lengthening in the target limb

• Fixed joint/muscle contracture

• Severe atrophy

• Concurrent treatment with an intrathecal baclofen

• Patients who have bleeding tendency or taking anti-coagulant

• Dysphagia and Breathing Difficulties

• History(within 4 months of screening visit) Planned(during study period) treatment with Botulinum Toxin

• Known allergy or sensitivity to study medication or its components

• Concurrent or planed Muscle relaxants and/or benzodiazepine medication If patient has taken these medication stable from one month before screening and no treatment changes are not planned during the study, participation is allowed.

• Current Physical, occupational, Splinting therapy These therapy regimens will be permitted if they have been stable in the one month before screening; no treatment and no changes are planned during the study.

• Patient who are participating in other clinical trials at the screening

• Females who are pregnant, breastfeeding, or planning a pregnancy during the study period, or female of childbearing potential, not using a reliable means of contraception.

• Patients who are not eligible for this study at the discretion of the investigator.

Related Conditions & MeSH terms

• Muscle Spasticity

Intervention

Drug:
• CORETOX®
Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U.
• BOTOX®
Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U.

Locations

Country	Name	City	State
Korea, Republic of	Asan Medical Center	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Medy-Tox

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MAS(Modified Ashworth Scale)of wrist flexor	Change from baseline at week 4 for wrist flexor muscle tone as measured on the MAS(Modified Ashworth Scale)	4 weeks
Secondary	MAS(modified Ashworth Score)of elbow and finger flexor	Change from baseline at week 4 for elbow flexor and finger flexor muscle tone as measured on MAS	4 weeks after injection
Secondary	MAS(modified Ashworth Score)of wrist, elbow and finger flexor	Change from baseline at week 8, 12 for wrist flexor, elbow flexor and finger flexor muscle tone as measured on MAS	8, 12 weeks after injection
Secondary	Percentage of treatment responder at week 4, 8, 12 after injection	A treatment response is defined as 1-point improvement on the MAS of injection site	4, 8, 12 weeks after injection